Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma
Annamaria Gulla,Eugenio Morelli,Megan Johnstone,Marcello Turi,Mehmet K Samur,Cirino Botta,Selma Cifric,Pietro Folino,Delaney Vinaixa,Francesca Barello,Cole Clericuzio,Vanessa Katia Favasuli,Domenico Maisano,Srikanth Talluri,Rao H Prabhala,Giada Bianchi,Mariateresa Fulciniti,Kenneth Wen,Keiji Kurata,Jiye Liu,Johany Penailillo,Alberto Bragoni,Anna Sapino,Paul G Richardson,Dharminder Chauhan,Ruben D Carrasco,Teru Hideshima,Nikhil C Munshi,Kenneth C Anderson,Mehmet K. Samur,Paul G. Richardson,Ruben D. Carrasco,Nikhil C. Munshi,Kenneth C. Anderson
DOI: https://doi.org/10.1182/blood.2023022777
IF: 20.3
2024-03-31
Blood
Abstract:Loss of GABARAP abrogates the surface exposure of calreticulin in dying cancer cells, thus reducing anti-MM immune response after bortezomib Immunogenicity can be restored by combining bortezomib with an autophagy inducer, providing the framework for their clinical translation Immunogenic cell death (ICD) is a form of cell death by which cancer treatments can induce a clinically relevant anti-tumor immune response in a broad range of cancers. In multiple myeloma (MM), the proteasome inhibitor bortezomib is an ICD inducer and creates durable therapeutic responses in patients. However, eventual relapse and resistance to bortezomib appear inevitable. Here, by integrating patient transcriptomic data with an analysis of calreticulin (CRT) protein interactors, we found that GABARAP is a key player whose loss prevented tumor cell death from being perceived as immunogenic after bortezomib treatment. GABARAP is located on chromosome 17p, which is commonly deleted in high-risk MM patients. GABARAP deletion impaired the exposure of the eat-me signal CRT on the surface of dying MM cells in vitro and in vivo, thus reducing tumor cell phagocytosis by dendritic cells and the subsequent anti-tumor T cell response. Low GABARAP was independently associated with shorter MM patient survival and reduced tumor immune infiltration. Mechanistically, we found that GABARAP deletion blocked ICD signaling by decreasing autophagy and altering Golgi apparatus morphology, with consequent defects in the downstream vesicular transport of CRT. Conversely, upregulating autophagy using rapamycin restored Golgi morphology, CRT exposure and ICD signaling in GABARAPKO cells undergoing bortezomib treatment. Therefore, coupling an ICD inducer, like bortezomib, with an autophagy inducer, like rapamycin, may improve patient outcomes in MM, where low GABARAP in the form of del(17p) is common and leads to worse outcomes.
hematology